Dependency on Src-Family Kinases for Recurrence of Androgen-Independent

Abstract

Prostate cancers that recur after so-called androgen ablation therapy ( CR-CaP ) are typically more aggressive, more likely to spread to local lymph nodes and bones, and less likely to respond to second-tier treatments, and therefore, contribute to significantly decreased patient survival. We posit that enzymes called Src-family kinases (SFK) are required for the progression to CR-CaP, and thus, targeting these enzymes should prevent CR-CaP formation to suppress their growth. We will use animal models of human and mouse CR-CaP in conjunction with genetic and biochemical experiments to show that SFK are critical to the formation of CR-CaP, and thus, are therapeutically targetable using SFK-specific drugs. Our important pre-clinical studies on the critical role played by SFK in CR-CaP disease will serve as the foundation to establish immediate clinical trials in which CaP patients are treated with drugs such as KX2-391 at the commencement of androgendeprivation therapy.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 2011
Accession Number
ADA552110

Entities

People

  • Gary Smith

Organizations

  • Health Research, Incorporated

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Androgens
  • Angiogenesis
  • Biomedical Research
  • Cancer
  • Cells
  • Clinical Trials
  • Endothelial Cells
  • Gene Expression
  • Growth Factors
  • Inhibition
  • Inhibitors
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Proteins
  • Tissues

Readers

  • Materials Science.
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech